The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move highlighting its leadership in the med-tech sector, Medtronic reported fiscal fourth-quarter net income of $1.24 billion, or 96 cents per share. According to the company, full-year fiscal revenue reached $36.33 billion, driven by what executives described as the strongest fourth-quarter top-line performance in a decade. Furthermore, the company issued forward-looking earnings guidance, projecting earnings per share to range between $5.90 and $6.00.
Medtronic's robust performance comes as the healthcare sector undergoes significant technical shifts, with Veeva Systems continuing its strategic migration to the Vault CRM platform to bolster margins. Compared to peers, market data shows Salesforce (CRM) facing cloud growth headwinds, which strengthens the position of companies with specialized enterprise platforms. Per market data, this revenue momentum places Medtronic in a competitive stance relative to its medical device industry peers.
Investors should monitor Medtronic (MDT) which closed at $85.40 and Veeva Systems (VEEV) at $182.15 (close June 2, 2026). Looking ahead, the market awaits the U.S. Core PCE Price Index release on May 28, 2026, a critical inflation gauge for the Fed that could impact valuations across the healthcare and technology growth sectors.
Update: Final data confirmed that Medtronic's fiscal fourth-quarter results narrowly exceeded analyst estimates, triggering a rise in the stock price. This upward movement suggests investors are prioritizing the current earnings beat over initial caution regarding the company's softer forward-looking guidance.